[Antiangiogenic drugs in refractory age-related macular degeneration]
Luxardo R, Augustovski F, Colaci C, Lazo E, Alfie V, García Martí S, Bardach A, Alcaraz A, Pichon-Riviere A
Record ID 32018004415
Spanish
Original Title:
Antiangiogénicos en degeneración macular asociada a la edad refractaria al tratamiento
Authors' recommendations:
Very low-quality evidence does not allow to draw conclusions about the effectiveness and/or safety of high-dose and/or high-frequency antiangiogenic drugs in age related macular degeneration (AMD) refractory and/or resistant to previous treatment with antiangiogenic drugs.
None of the clinical practice guidelines consulted mentions an increased dose and/or
frequency of antiangiogenic drugs as a therapeutic option to AMD resistant and/or refractory to previous treatment with antiangiogenic drugs. None of the coverage policies consulted mentions covering high-dose and/or high-frequency antiangiogenic drugs.
There are no economic evaluations that assess the impact of the antiangiogenic drug dose and/or frequency increase as a therapeutic option for AMD resistant and/or refractory to previous treatment with antiangiogenic drugs.
Details
Project Status:
Completed
Year Published:
2022
URL for published report:
https://www.iecs.org.ar/publicacion/?id=22217
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Macular Degeneration
- Angiogenesis Inhibitors
- Wet Macular Degeneration
- Intravitreal Injections
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.